Vaxcyte Announces $862.5 Million Public Offering
Palo Alto – February 5, 2024 – Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering. Partners John McKenna and Mark Weeks led the Cooley team advising Vaxcyte.
Vaxcyte offered 12,695,312 shares of common stock priced at $64 per share, which includes the full exercise of the underwriters’ option to purchase an additional 1,757,812 shares, along with pre-funded warrants to purchase 781,250 shares of common stock priced at $63.999 per underlying share. The offering closed on February 2, 2024.
BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities and Cantor acted as joint book-running managers for the offering. BTIG and Needham & Company acted as lead managers for the offering.
Cooley previously advised Vaxcyte on its $575 million public offering in May 2023, $690 million public offering in October 2022 and $100 million public offering in January 2022.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.